Negative immune checkpoint regulation by VISTA: A mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
Modern Pathology Aug 09, 2017
Kakavand H, et al. – The potential mechanisms of acquired resistance to anti–PD–1 were scrutinized in this trial, in longitudinally collected metastatic melanoma patient biopsies. The results observed that negative immune checkpoint regulation by VISTA represented a significant potential mechanism of acquired resistance in the study cohort. Downregulation of HLA–associated antigen presentation occurred with acquired resistance. Augmentation of the VISTA immune checkpoint pathway displayed as a promising therapeutic strategy in metastatic melanoma patients, especially those failing anti–PD–1 therapy. It necessitated additional research.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries